+44 20 8123 2220
info@marketpublishers.com

Global CD47 Inhibitor Drug Clinical Trials Insight 2028

https://marketpublishers.com/r/GBBEA4C66787EN.html
Date: August 2022
Pages: 132
Price: US$ 2,000.00 (Single User License)
ID: GBBEA4C66787EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global CD47 Inhibitor Drug Clinical Trials Insight 2028 Report Highlights:

CD47 Inhibitor Drug Market Trends and Future Prospects

Insight On More Than 50 CD47 Inhibitors Drugs In Clinical Trials

Orphan, Fast Track, Breakthrough Therapy Designation Insight

Insight On CD47 Inhibitors Drugs Biomarkers Sourced During Clinical Trials

CD47 Inhibitors Drug Clinical Trials Insight By Company, Indication and Phase

CD47 Inhibitors Drug Clinical Trials Insight As Mono and Combination Therapy

Global CD47 Inhibitor Drug Market Dynamics

Immunotherapy particularly with immune checkpoint inhibitor has shown to transform the global cancer therapeutics market. However, despite these huge advancements in the field of cancer therapeutics, the majority of patients does not respond to or develop resistance to immunotherapy, highlighting the need for additional approaches to expand cancer immunotherapy. In last few years, technological advancements have enabled the identification of various other receptors which can be of therapeutic potential. Recently, CD47 has gained major focus of researchers as therapeutic potential target for drug development.

+44 20 8123 2220
info@marketpublishers.com

Till date, no CD47 targeting antibody has gained market authorization. However, the pipeline is highly crowded indicating encouraging role of CD47 targeting therapies in the management of cancer. Magrolimab developed by GlaxoSmithKline is one of the most promising CD47 targeting antibodies in clinical development. Currently, the company is evaluating the drug in phase-III clinical trial accessing the efficacy and safety of Magrolimab in combination with azacitidine for the management of acute myeloid leukemia and myelodysplastic syndrome. The drug has received fast track designation from US FDA and is expected to enter the market by 2024.

Apart from this, several other pharmaceutical giants have developed a robust clinical pipeline of the CD47 targeting therapies which are being evaluated in various phase-I/II clinical trials. The companies have also adopted strategic alliances such as collaboration, partnership, or acquisitions to maintain their competitive edge in the market. For instance, AbbVie entered into collaboration with I-Mab for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.

To further enhance the therapeutic potential of CD47 targeting therapies, researchers have also initiated clinical trials evaluating their role in combination therapies. For instance, Arch Oncology and Merck are currently conducting phase-I/II clinical trial to evaluate AO-176, the Company’s novel anti-CD47 antibody in combination with Keytruda for the treatment of patients with select solid tumors including relapsed, platinum-resistant ovarian cancer, endometrial cancer, and gastroesophageal cancer. Another, ALX Oncology in collaboration with Eli Lilly to evaluate the combination of ALX148, a next generation CD47 blocker and Cyramza for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer. It is suggested that combination therapies will dominate the global market owing to their enhanced efficacy and specificity towards the cancer cells.

US and Chinese pharmaceutical firms are currently dominating the CD47 inhibitors drugs RandD landscape driven by encouraging clinical pipeline, increasing cancer research activities to find innovative therapies, and favorable government policy framework. For instance in 2022, US FDA has granted orphan drug designation to AO-176 for the management of relapsed or refractory multiple myeloma. AO-173 is investigational CD47 targeting monoclonal antibody developed by Arch Oncology. Another, ALX Oncology has also received orphan drug designation for evorpacept for the treatment of patients with acute myeloid leukemia. The orphan drug designation is

+44 20 8123 2220
info@marketpublishers.com

associated with incentives which favor the rapid approval of the drug in the region.

As per our report findings, the global CD47 market opportunity is expected to surpass US$ 2 Billion by 2028. This is mainly due to large number of clinical pipeline products which are expected to gain approval and their encouraging response in the management of cancer. Further, the huge investments by pharmaceutical giants and special designations also suggest the promising growth of the market.

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global CD47 Inhibitor Drug Clinical Trials Insight 2028
Product link: https://marketpublishers.com/r/GBBEA4C66787EN.html
Price: US$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GBBEA4C66787EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970